US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) exceeded analysts’ estimates on both revenue and earnings with its third-quarter financial results.
Revenues rose 32% to $2.29 billion, beating estimates of $2.09 billion, according to IBES data from Refinitiv.
Net profit rose to $842.1 million, or $7.39 per share, in the three months ended September 30, from $669.6 million, or $5.86 per share, a year earlier. Excluding items, Regeneron earned $8.36 per share, beating estimates of $7.14.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze